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OBJECTIVE—Recent studies in humans and animal models of
obesity have shown increased adipose tissue activity of 11-
hydroxysteroid dehydrogenase type 1 (11-HSD1), which ampli-
ﬁes local tissue glucocorticoid concentrations. The reasons for
this 11-HSD1 dysregulation are unknown. Here, we tested
whether 11-HSD1 expression, like the metabolic syndrome, is
“programmed” by prenatal environmental events in a nonhuman
primate model, the common marmoset monkey.
RESEARCH DESIGN AND METHODS—We used a “fetal
programming” paradigm where brief antenatal exposure to glu-
cocorticoids leads to the metabolic syndrome in the offspring.
Pregnant marmosets were given the synthetic glucocorticoid
dexamethasone orally for 1 week in either early or late gestation,
or they were given vehicle. Tissue 11-HSD1 and glucocorticoid
receptor mRNA expression were examined in the offspring at 4
and 24 months of age.
RESULTS—Prenatal dexamethasone administration, selectively
during late gestation, resulted in early and persistent elevations
in 11-HSD1 mRNA expression and activity in the liver, pancreas,
and subcutaneous—but not visceral—fat. The increase in 11-
HSD1 occurred before animals developed obesity or overt fea-
tures of the metabolic syndrome. In contrast to rodents, in utero
dexamethasone exposure did not alter glucocorticoid receptor
expression in metabolic tissues in marmosets.
CONCLUSIONS—These data suggest that long-term upregula-
tion of 11-HSD1 in metabolically active tissues may follow
prenatal “stress” hormone exposure and indicates a novel mech-
anism for fetal origins of adult obesity and the metabolic
syndrome. Diabetes 58:2873–2879, 2009
T
he metabolic syndrome and its component fea-
tures (central obesity, insulin resistance/type 2
diabetes, hypertension, dyslipidemia) have been
causally linked to early life events as marked by
low birth weight and other features of an adverse intra-
uterine environment (1,2). Two major etiological hypoth-
eses of the “developmental origins” effects have been
proposed: malnutrition and glucocorticoid overexposure
(3,4). These mechanisms of “programming” may be linked
because maternal undernutrition increases maternal glu-
cocorticoid concentrations and reduces the placental en-
zymatic barrier to maternal glucocorticoids in rats, thus
increasing fetal glucocorticoid exposure (5). Moreover,
maternal glucocorticoid administration reduces food in-
take in rodents (6).
The processes that link intrauterine insults and later risk
of the metabolic syndrome are not yet understood. The
metabolic syndrome resembles the rare Cushing’s syn-
drome of circulating glucocorticoid excess, but in uncom-
plicated metabolic syndrome, plasma cortisol levels are
not raised, spawning the suggestion that increased tissue
sensitivity to glucocorticoid action may be important in its
pathogenesis (7). In the major metabolic organs, tissue
sensitivity and exposure to glucocorticoids are determined
by the density of intracellular glucocorticoid receptors and
the activity of the microsomal enzyme 11-hydroxysteroid
dehydrogenase type 1 (11-HSD1) which catalyzes the
regeneration of active cortisol (corticosterone in rodents)
from inert cortisone (11-dehydrocorticosterone) (7). 11-
HSD1 is highly expressed in liver and adipose tissue,
where glucocorticoids reduce insulin sensitivity and ac-
tion (7).
In obese humans and in monogenic obesity in rodents,
there is a selective increase in 11-HSD1 mRNA and
activity in adipose tissues (8–10). Increased 11-HSD1 in
liver is found in other causes of metabolic syndrome, such
as myotonic dystrophy (11). Transgenic overexpression of
11-HSD1 selectively in adipose tissue in mice recapitu-
lates all the major features of metabolic syndrome without
changes in circulating steroid levels (12), whereas overex-
pression of 11-HSD1 in liver alone produces an attenu-
ated syndrome with insulin resistance, dyslipidemia, and
hypertension, but not hyperglycemia or obesity (13). Con-
versely, 11-HSD1 knockout mice are insulin sensitized
and resist metabolic syndrome with dietary obesity (14).
However, genetic variation in the HSD1B1 gene does
not associate with obesity (15), suggesting the cause of
increased 11-HSD1 in adipose tissue in obesity is envi-
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regulate 11-HSD1 in the short term, attempts to
chronically induce 11-HSD1 in adipose tissue by nonge-
netic approaches have been unsuccessful. In particular,
high-fat diets in rodents downregulate 11-HSD1 in adi-
pose tissue (16), although this does not appear to occur in
humans (17), underlining the importance of relevant mod-
els of the human situation.
Here, we have explored the early life antecedents of
metabolic syndrome and especially 11-HSD1 expression
in metabolic tissues in a nonhuman primate model (the
common marmoset monkey) of fetal programming.
RESEARCH DESIGN AND METHODS
Experiments were conducted in accordance with the European Communities
Council directive of 24 November 1986 (86/EEC) and were approved by the
Lower Saxony Federal State Ofﬁce for Consumer Protection and Food Safety,
Germany. Adult common marmoset monkeys (Callithrix jacchus) were
obtained from the breeding colony of the German Primate Center in Go ¨ttin-
gen, Germany. Breeding and experimental animals were housed in pairs in
wire mesh cages (76  50  125 cm) under controlled and standardized
conditions (lights on 7:00 A.M.; lights off 7:00 P.M.; temperature 26  1.5°C;
relative humidity 60–80%; air exchange six to eight times per hour). Animals
were fed a pelleted marmoset diet (Spezialdia ¨ten; ssniff, Soest, Germany;
www.ssniff.de) ad libitum. This diet (Mar V3843; ssniff) contained, per
kilogram of dry matter, 26% crude protein, 7% fat, 2.5% crude ﬁber, 43.8%
starch and saccharides, 1% calcium, 0.7% inorganic phosphate, 3,000 IU
vitamin D3, and 15.6 megajoules (MJ) digestible energy. In addition, in the
morning each animal was offered 30 g of a mash that contained 21% crude
protein, 14% fat, 10% crude ﬁber, 41% starch and saccharides, 0.95% calcium,
and 0.67% organic phosphate in the dry matter and 5,500 IU vitamin D3 and
17.9 MJ digestible energy per kilogram. In the afternoon, each animal received
30 g of clean cut fruits or vegetables. Water was always available.
Time mating and dexamethasone administration. Plasma progesterone
concentration was regularly measured in the breeding females for ovarian
cycle determination and to detect pregnancy. During the adaptation period,
animals were given intramuscular injections of a prostaglandin F2 analog
(Estrumate, 2.5 g cloprostenol per animal; Essex-Tierarznei, Munich, Ger-
many) on day 14 of the luteal phase to prevent pregnancy. After adaptation,
plasma progesterone concentration was measured in samples taken every 1–2
days between day 7 and day 13 of the follicular phase, and ovulation was
assumed to have taken place if plasma progesterone level increased from 10
to 15 ng/ml. The day of ovulation was considered as day 0, and pregnancy
was conﬁrmed by ultrasound examination after 4 and 8 weeks.
Although marmoset monkeys have a fully functional HPA (hypothalamic-
pituitary-adrenal) axis, they exhibit relatively high physiological cortisol
concentrations (18). Therefore, to determine a suitable administration dose of
dexamethasone, we undertook a pilot study in which pregnant marmosets
were administered a range of doses of dexamethasone, between 0.05 and 10
mg/kg per day orally. Dexamethasone tablets (0.5, 1.5, or 4 mg; Jenapharm,
Jena, Germany) were dissolved in 0.4 ml of tap water and mixed with 1.6 ml
NutriCal (Albrecht, Aulendorf, Germany). The mixture was taken voluntarily
by all animals. We found 1 or 5 mg/kg dexamethasone per day effectively
suppressed maternal endogenous cortisol production without adverse effects,
whereas 10 mg/kg induced abortion and caused symptoms of glucocorticoid
deﬁciency after cessation of dexamethasone administration. We used 5 mg/kg
dexamethasone per day in all subsequent experiments. This dose is signiﬁ-
cantly higher than those shown to produce programming effects in rodents
(19) or vervet monkeys (20), and it reﬂects the relative resistance of the
marmoset to glucocorticoid action (18). Pregnant marmoset monkeys (n  10
per group) were given dexamethasone or vehicle either early in pregnancy or
during late gestation. In marmosets, the average expected full-term gestation
is 145 days. With early administration (early dexamethasone), dexamethasone
was given daily for 7 days during late ﬁrst trimester (gestation day 42–48) to
target the maturational stage of neurogenesis in this primate (21), and
therefore a putative sensitive period for inducing acute central effects with
long-term consequences. For late administration (late dexamethasone), dexa-
methasone was administered daily for 7 days in the late second trimester
(gestation day 90–96) to mimic the therapeutic use of glucocorticoids in
humans to promote fetal maturity in mothers at risk for preterm delivery, and
therefore of particular translational relevance.
At birth, the neonates were sexed and weighed. To ensure that the breeding
pair could bring up the young, one infant was removed in cases of triplet
litters. No surplus baby food was given to the newborn monkeys. The offspring
were kept with their parents until weaning at 6 months of age. One male
offspring from each litter was recruited into the study groups.
Plasma glucose and triglycerides. At 6, 12, 18, and 24 months of age, oral
glucose tolerance tests were carried out after an overnight (15 h) fast. Glucose
was given in a solution of 500 g/l glucose and 300 g/l gum Arabic (to increase
viscosity and prevent spillage). All animals took the glucose solution volun-
tarily. Plasma glucose concentrations from fasting and samples taken 20 min
after the oral glucose load (2 g/kg) were measured with the Ectachem DT60
system (Ortho-Clinical Diagnostics, Johnson & Johnson, Rochester, NY), and
A1C was determined using a Bio-Rad Micromat II (Bio-Rad, Perth, U.K.).
Triglycerides were measured enzymatically with Inﬁnity triglycerides liquid
stable reagent (ThermoTrace; Alpha Laboratories, Hampshire, U.K.). We were
unable to measure plasma insulin concentrations because of the lack of a
reliable assay for marmoset insulin. Urine samples were collected in the
morning by placing animals in collecting cages, and cortisol and creatinine
concentrations were determined by liquid chromatography–tandem mass
spectrometry as previously described (22).
Tissue processing. At 4 months of the age, animals had liver biopsies under
general anesthesia with ultrasound guidance, and samples were stored at
	80°C for subsequent analysis. The offspring were killed at 24 months of age.
Animals were anesthetized by intramuscular injections of alphaxalon (6.75
mg/kg) plus alphadolon (Saffan 2.25 mg/kg; Schering-Plough Animal Health,
Welwyn Garden City, U.K.), glycopyrroniumbromid (Robinul 0.02 mg/kg;
Riemser, Greifswald, Germany), and diazepam (0.25 mg/kg; Ratiopharm, Ulm,
Germany) and killed by an intracardiac overdose of ketamine. Tissues were
quickly collected, snap-frozen in liquid nitrogen, and stored at 	80°C for
subsequent analyses.
Real-time PCR. RNA was extracted from biopsy or necropsy samples using
TRIzol reagent (Life Technologies, Invitrogen, Paisley, U.K.). cDNA was
created, and real-time PCR was performed as previously described (20) to
quantify phosphoenolpyruvate carboxykinase (PCK1), 11-HSD1, and glu-
cocorticoid receptor- mRNA expression. The following primers and probes
were used in PCR: PEPCK 5
-GCTGGATGTCAGAGGAGGATTTTGAG-3

(forward), 5
-CCATGCTGAATGGGATGACGTACATG-3
 (reverse), and
5
-6-FAM-CAATGCCAGGTTCCCGGGGTG-TAMRA-3
 (probe); 11-HSD1
5
-CCTCAGCGCACTACATTGCTGGC-3
 (forward), 5
-GAGCATGTCTAGTC-
CTCCCATGAGC-3
 (reverse), and 5
-6-FAM-GGAAGACATGGCCTTCGCAGAGC-
TAMRA-3
 (probe); glucocorticoid receptor- 5
-CATTGTCAAGAGGGAAGG-
AAACTC-3
 (forward), 5
-GATTTTCAACCACTTCATGCATAGAA-3
 (reverse),
and 5
-6-FAM-TTTGTCAGTTGATAAAACCGCTGCCAGTTCT-TAMRA-3
 (probe).
18S rRNA primers and probes (Applied Biosystems, Cheshire, U.K.) were used
to normalize the transcript levels. A standard curve for each primer-probe set
was generated in triplicate by serial dilution of cDNA that was pooled from
several subjects. Each sample was run in duplicate, and the mean values of the
duplicates were used to calculate the transcript level from the standard curve.
The results are expressed as arbitrary units.
11-HSD1 activity. Under in vitro conditions, 11-HSD1 is bidirectional, and
the more stable dehydrogenase reaction was measured as previously de-
scribed (23). In brief, samples were homogenized in Krebs buffer at pH 7.4,
and then 600 g/ml protein was incubated at 37°C with 2 mmol/l NADP and
TABLE 1
Maternal and offspring characteristics
Maternal age
(years)
Gestational period
(days) Litter size
Male-to-female
ratio*
Male birth
weight (g)
Control 5.0  0.3 144.4  0.7 2.9  0.2 1.6 32.0  0.8
Early-Dex 4.4  0.5 144.7  1.0 2.8  0.2 1.8 30.4  0.7
Late-Dex 4.0  0.5 145.7  0.8 2.8  0.3 2.1 32.0  1.1
*Data is for litters with at least one male offspring; pure female litters were not considered. Early-Dex, early-gestation dexamethasone;
Late-Dex, late-gestation dexamethasone.
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3H]4cortisol (100 nm) for 24 h. The conversion of [
3H]4cortisol to
[
3H]4cortisone was quantiﬁed in the samples after separation by high-perfor-
mance liquid chromatography with online liquid scintillation detection.
Hepatic PEPCK activity. PEPCK activity was measured in liver cytosolic
fraction homogenates from 24-month-old marmosets, as described previously
(19). In short, the cytosolic fraction (1 mg) was assayed in 1 ml buffer
containing 50 mmol/l HEPES (pH 6.5), 50 mmol/l sodium bicarbonate, 1
mmol/l MgCl2, 0.25 mmol/l NADH, 1.0 mmol/l phosphoenolpyruvate, and 1.5
units malate dehydrogenase. The absorbance of NADH was determined at 340
nm at 30°C. After a stable signal was obtained, the reaction was initiated by
addition of 0.15 mmol/l 2
deoxyguanosine 5
diphosphate. After 3 min of
incubation, a decrease in absorbance was measured. A reaction mixture
without bicarbonate was used as a negative control.
Area under the glucose versus time curve. The area under the curve
glucose versus time was the product of mean glucose concentration during
the oral glucose tolerance test (mmol/l) and the exact time interval (min)
between application of the glucose solution and blood sampling thereafter.
Statistics. All data are the means  SEM. Data were compared using one- or
two-way ANOVA followed by Newman-Keuls or Bonferroni post hoc multiple
comparisons test, where appropriate. Values were considered signiﬁcantly
different at P  0.05.
RESULTS
Litter size and body weight. There were no signiﬁcant
differences in maternal age. It was not possible to accu-
rately quantify maternal food intake under the social
housing conditions used, but dexamethasone did not sig-
niﬁcantly affect maternal weight gain during pregnancy.
Similarly, there were no differences in gestational period
or litter size among the dexamethasone administration
groups (Table 1). Dexamethasone, given in either early or
late gestation, had no signiﬁcant effect on offspring birth
weight. The offspring of mothers that received dexameth-
asone late in pregnancy showed higher rates of weight
gain postnatally compared with controls, and, overall,
late-administration dexamethasone had a signiﬁcant effect
on offspring body weight across the 24 months (P  0.04),
although by 24 months of age, there were no statistically
signiﬁcant differences in body weight by dexamethasone
administration group (Fig. 1).
Plasma glucose and triglycerides. The offspring in the
three groups had similar plasma fasting and reactive glucose
concentrations at 6, 12, or 18 months of age (Table 2).
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FIG. 1. Effect of prenatal dexamethasone on offspring body weight.
Graph shows body weight at different ages in offspring of mothers that
received vehicle (Control), or dexamethasone during early (Early-
DEX) or late (Late-DEX) pregnancy. *P < 0.05 compared with control
animals.
TABLE 2
Offspring plasma glucose, A1C, and triglycerides
Control Early-DEX Late-DEX
6 months
Fasting glucose (mmol/l) 6.5  0.3 7.3  0.6 6.2  0.7
OGTT 20-min glucose (mmol/l) 11.7  1.2 12.4  0.9 11.8  0.9
AUC0–20min glucose 181.8  11.6 190.1  13.1 180.7  14.5
A1C (%) 4.4  0.3 4.7  0.7 4.6  0.2
Fasting triglycerides (mmol/l) 0.68  0.05 0.71  0.10 0.78  0.06
Urine cortisol (g/mg creatinine) 11.7  2.1 11.1  1.0 13.4  6.0
12 months
Fasting glucose (mmol/l) 7.3  0.5 7.4  1.0 7.9  0.7
20-min glucose (mmol/l) 11.4  1.0 12.1  1.4 13.3  1.3
AUC0–20min glucose 187.8  10.2 177.3  16.7 214.7  18.5
A1C (%) 4.6  0.1 4.6  0.2 4.9  0.5
Fasting triglycerides (mmol/l) 0.81  0.10 0.67  0.04 0.90  0.14
Urine cortisol (g/mg creatinine) 7.3  1.4 6.7  0.8 7.0  1.2
18 months
Fasting glucose (mmol/l) 7.5  0.9 7.9  0.8 8.9  1.2
20-min glucose (mmol/l) 11.0  1.1 12.1  1.7 12.4  1.6
AUC0–20min glucose 186.4  10.0 184.7  15.5 218.2  26.9
A1C (%) 4.6  0.2 4.8  0.4 4.8  0.5
Fasting triglycerides (mmol/l) 0.81  0.12 0.98  0.21 2.12  0.67
Urine cortisol (g/mg creatinine) 7.4  1.4 4.1  0.5 5.6  1.0
24 months
Fasting glucose (mmol/l) 7.5  0.7 7.6  0.6 9.4  0.7*
20-min glucose (mmol/l) 11.9  1.0 11.8  0.6 13.3  1.1
AUC0–20min glucose 194.2  8.9 200.0  13.5 237.9  12.6
A1C (%) 4.5  0.2 4.7  0.3 5.2  0.5
Fasting triglycerides (mmol/l) 1.39  0.56 1.36  0.13 2.18  0.28
Urine cortisol (g/mg creatinine) 9.6  2.1 6.8  1.4 9.2  1.5
*P  0.05 is relative to control or early-gestation dexamethasone. AUC, area under the curve in oral glucose tolerance test; Early-Dex,
early-gestation dexamethasone; Late-Dex, late-gestation dexamethasone; OGTT, oral glucose tolerance test.
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dexamethasone during late pregnancy had higher fasting
plasma glucose concentration than controls (Table 2).
Although 20-min (postload) plasma glucose concentra-
tions did not signiﬁcantly differ, there was a strong trend
for increased area under the curve for glucose in Late-
dexamethasone animals compared with controls (P 
0.056). Fasting triglycerides also trended to be higher in
late-dexamethasone than in control offspring at 24 months
(P  0.06). Early administration of dexamethasone did not
alter plasma glucose (fasting or reactive) or triglyceride
concentrations in the offspring (Table 2).
The effect of prenatal dexamethasone on 11-HSD1
expression in key metabolic tissues. Early dexameth-
asone administration did not affect expression of 11-
HSD1 mRNA in the liver, pancreas, or adipose tissue of the
offspring. In contrast, offspring of mothers that received
late administration of dexamethasone had signiﬁcantly
higher 11-HSD1 mRNA levels in the liver at 4 months of
age, and this persisted into adulthood (Fig. 2). Similarly,
these animals showed increased 11-HSD1 mRNA expres-
sion in the pancreas and subcutaneous, but not peritoneal,
adipose tissue (Fig. 3). In control 2-year-old marmosets,
11-HSD1 mRNA expression was nearly 2.5-fold higher in
subcutaneous than peritoneal adipose tissue. This differ-
ence rose to ﬁvefold in animals that had received dexa-
methasone in late gestation.
The changes in 11-HSD1 mRNA expression were func-
tionally signiﬁcant because 11-HSD1 activity assays
showed late-dexamethasone animals had parallel in-
creases in 11-HSD1 activity in their livers (Fig. 2). More-
over, this was associated with signiﬁcantly increased
mRNA expression and activity of PEPCK1 (Fig. 4), the
rate-limiting enzyme of gluconeogenesis and an important
target for glucocorticoids and for glucocorticoid program-
ming in rodents (19). In contrast to prenatal dexametha-
sone programming in rats (19), neither early nor late
administration of dexamethasone had any effect on glu-
cocorticoid receptor mRNA levels in any of the tissues
examined (Fig. 5). Prenatal dexamethasone administration
did not signiﬁcantly affect urinary cortisol concentrations,
suggesting that the induction of 11-HSD1 in metabolic
tissues is not attributable to elevated circulating glucocor-
ticoids per se (Table 2).
DISCUSSION
Here, we demonstrate, in a nonhuman primate model, that
prenatal dexamethasone administration causes permanent
tissue-speciﬁc changes in expression of 11-HSD1, a gene
that has emerged as an important player in the pathogen-
esis of obesity and the metabolic syndrome. Thus, prenatal
dexamethasone exposure was associated with elevated
11-HSD1 expression in key metabolic organs, such as
liver, pancreas, and subcutaneous fat, but not visceral
adipose tissue. The changes in 11-HSD1 expression were
seen when dexamethasone was administered selectively in
late gestation, congruent with the critical window of
sensitivity for programming key target organs involved in
glucose metabolism in various other animal models
(3,19,20). As in the African vervet monkey (20), but unlike
rodent programming models (19), prenatal dexametha-
sone exposure was not associated with a signiﬁcant reduc-
tion in marmoset birth weight. The reasons for this
discrepancy are unclear, but perhaps reﬂect the fact that
birth weight is a relatively crude measure of organ growth,
and antenatal insults may alter offspring physiology with-
out necessarily having a signiﬁcant effect on birth weight.
In most rodent models, in which antenatal glucocorticoids
reliably reduce birth weight, glucocorticoid exposure typ-
ically extends over a relatively larger fraction of the fetal
period (i.e., 5–6 days of the 21–22 day rat gestation) than
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FIG. 2. Effect of prenatal dexamethasone on 11-HSD1 expression in
the liver. Hepatic 11-HSD1 mRNA expression was measured by real-
time PCR in 4-month-old (A) and 24-month-old (B) offspring of mothers
that received vehicle (Control) or dexamethasone during early (Early-
DEX) or late (Late-DEX) pregnancy. 11-HSD1 enzyme activity was
assessed in 24-month-old livers (C). Results represent mRNA expres-
sion relative to control animals. *P < 0.05 compared with control
animals.
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dexamethasone does not inevitably reduce birth weight in
humans (24).
The increase in 11-HSD1 mRNA expression in animals
exposed to dexamethasone in late gestation was observed,
at least in the liver, at an early age (4 months) and
persisted into adulthood. Marmosets are normally lean,
and the animals in our study were killed at a relatively
young age. Although these animals did not have a postna-
tal challenge (such as high-fat feeding) and were not
overtly obese, late-gestation dexamethasone administra-
tion was associated with mild hyperglycemia and border-
line hypertriglyceridemia. Elevated tissue levels of 11ß-
HSD1 preceded these metabolic changes, suggesting that
these are primary. In support of this notion, a recent study
showed that rats born to diabetic mothers, which also
develop obesity and insulin resistance, have similar early
increases in 11-HSD1 mRNA and activity in the liver and
adipose tissue (25). Taken together, these data suggest
that 11-HSD1 is inﬂuenced by diverse intrauterine envi-
ronmental insults, and they may provide a common mech-
anism in programming the metabolic syndrome. Postnatal
overfeeding (by reducing litter size in the immediate
neonatal period) in rats has also been shown to result in
obesity associated with increased adipose tissue glucocor-
ticoid receptor and 11-HSD1 mRNA expression. Interest-
ingly, whereas the change in glucocorticoid receptor was
evident as early as postnatal day 21, increased 11-HSD1
expression was only seen in adult animals (26).
In marmosets, subcutaneous fat had more 11-HSD1
mRNA expression than peritoneal adipose tissue, and
late-gestation dexamethasone increased 11-HSD1 mRNA
expression selectively in the subcutaneous fat depot.
Interestingly, a recent human study showed that increased
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FIG. 3. 11-HSD1 expression in adipose tissue and pancreas. 11-HSD1
mRNA expression was measured in subcutaneous fat (A), peritoneal fat
(B) and pancreas (C) of in 24-month-old offspring of mothers that
received vehicle (Control), or dexamethasone during early (Early-
DEX) or late (Late-DEX) pregnancy. Results represent mRNA expres-
sion relative to control animals. *P < 0.05.
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FIG. 4. Effect of prenatal dexamethasone on PEPCK expression in
the liver. Hepatic PEPCK mRNA (A) and activity (B) were measured
in 24-month-old offspring of mothers that received vehicle (Control)
or dexamethasone during early (Early-DEX) or late (Late-DEX)
pregnancy. Results represent mRNA expression or enzyme activity
relative to control animals. *P < 0.05 compared with control
animals.
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adipose tissue was associated with a worsening of the
metabolic syndrome (27). The reasons for the depot-
speciﬁc effects of late-gestation dexamethasone are un-
clear. Transcriptional regulation of the HSD11B1 gene is
complex and highly tissue speciﬁc, but the mechanisms
that underlie this tissue-speciﬁc regulation or its dysregu-
lation in obesity are unknown. A number of factors,
including the C/EBP family of transcription factors, insu-
lin, proinﬂammatory mediators, as well as glucocorticoids
themselves have been shown to inﬂuence 11-HSD1
mRNA expression and/or activity (28).
Overactivity of 11-HSD1 in the liver might also contrib-
ute to the metabolic syndrome because glucocorticoids
regulate a number of pathways that control hepatic glu-
cose and lipid metabolism (29). In support of this, the
offspring of mothers that were administered dexametha-
sone during late gestation showed enhanced hepatic
activity of PEPCK1, the rate-limiting enzyme of gluco-
neogenesis, suggestive of increased hepatic glucose out-
put. Similarly, glucocorticoids are known to inhibit insulin
secretion (30), and increased activity of 11-HSD1 in the
pancreas in rodents associates with -cell dysfunction and
may contribute to the pathogenesis of hyperglycemia (31).
In rodent models, in utero exposure to dexamethasone
has also been associated with permanent tissue-speciﬁc
changes in glucocorticoid receptor mRNA expression,
downregulation in the hippocampus, and increased ex-
pression in adipose tissue and liver (1). However, in the
current study, we observed no signiﬁcant differences in
tissue glucocorticoid receptor expression between mar-
mosets that received dexamethasone in utero and con-
trols. The reasons for this discrepancy are unclear, but
they are unlikely to be due the fact that New World
monkey species have altered glucocorticoid receptor sig-
naling and regulation (18) because a similar observation
was made in an Old World species (the vervet monkey)
(20). This underlines a possible programming difference in
metabolic organs between rodents and primates, with
prenatal glucocorticoid exposure targeting primarily glu-
cocorticoid receptors in the former (19,32) but primarily
11-HSD1 in the latter.
In summary, antenatal glucocorticoid excess in marmo-
sets causes persistent increases in 11-HSD1 expression in
adipose tissue and other metabolic organs, suggesting that
long-term upregulation of 11-HSD1 in adipose tissues
may follow prenatal “stress.” Because increased adipose
or hepatic 11-HSD1 has been implicated in the pathogen-
esis of obesity and the metabolic syndrome, these data
indicate, ﬁrst, a novel mechanism for fetal origins of adult
obesity and the metabolic syndrome and, second, a poten-
tial mechanism to explain the upregulation of 11-HSD1
seen in humans with metabolic syndrome/obesity.
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FIG. 5. Effect of dexamethasone on glucocorticoid receptor expression. Tissue glucocorticoid receptor mRNA was measured in liver (A),
subcutaneous fat (B), peritoneal fat (C), and pancreas (D) by real-time PCR in 24-month-old offspring of mothers that received vehicle (Control)
or dexamethasone during early (Early-DEX) or late (Late-DEX) pregnancy. Results are expressed as mRNA expression relative to control
animals.
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